PfizerRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Pfizer (PFE) reported revenue of $15.03B in Q2 2026, with Biopharma its largest revenue segment at 98%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
PfizerDiversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
Pfizer (PFE) is a Drug Manufacturers - General company. Diversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China. It was founded in 1849, is headquartered in New York, NY and employs about 88,000 people.
As of 2026-Q1, Pfizer's revenue breaks down across Biopharma (98%), Segment Reporting, Reconciling Item, Corporate Non (2%). See the revenue-by-segment chart for the full mix.
Track Pfizer's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 23, 2026.
Sterling groups Pfizer in the GLP-1 sector, alongside Amgen (AMGN), Roche (RHHBY), AstraZeneca (AZN), Merck & Co. (MRK) and AbbVie (ABBV). Sterling also tracks it in the Vaccines sector.
If you are researching Pfizer, also look at Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.